Evidence map›Paper›PMID 35184400›Full record

Observational studyClinical and translational medicine2022

Osteomodulin attenuates smooth muscle cell osteogenic transition in vascular calcification.

Nikolaos T Skenteris, Till Seime, Anna Witasp, Eva Karlöf, Grzegorz B Wasilewski, Marina A Heuschkel, Armand M G Jaminon, Loureen Oduor, Robert Dzhanaev, Malin Kronqvist and 14 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. ASPORIN: A root of the matter in tumors and their host environment.Biochimica et biophysica acta. Reviews on cancer · 2024
    Review
  17. Article
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 6 countries.

Nikolaos T SkenterisCardiovascular Medicine Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Till SeimeDivision of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Anna WitaspDivision of Renal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
Eva KarlöfDivision of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Grzegorz B WasilewskiDepartment of Biochemistry and CARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands.
Marina A HeuschkelDepartment of Biochemistry and CARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands.
Armand M G JaminonDepartment of Biochemistry and CARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands.
Loureen OduorDepartment of Clinical Sciences Malmö and Cardiology, Skåne University Hospital, Lund University, Lund, Sweden.
Robert DzhanaevDepartment of Biochemistry and CARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands.
Malin KronqvistDivision of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Mariette LengquistDivision of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Frederique E C M PeetersDepartment of Cardiology and CARIM, School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, Netherlands.
Magnus SöderbergCardiovascular, Renal and Metabolism Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Rebecka HultgrenDivision of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Joy RoyDivision of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Lars MaegdefesselCardiovascular Medicine Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Hildur ArnardottirCardiovascular Medicine Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Eva BengtssonDepartment of Clinical Sciences Malmö and Cardiology, Skåne University Hospital, Lund University, Lund, Sweden.
Isabel GoncalvesDepartment of Clinical Sciences Malmö and Cardiology, Skåne University Hospital, Lund University, Lund, Sweden.
Thomas QuertermousDepartment of Cardiovascular Medicine, University of Stanford, Stanford, California, USA.
Claudia GoettschDepartment of Internal Medicine I-Cardiology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Peter StenvinkelDivision of Renal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
Leon J SchurgersDepartment of Biochemistry and CARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, Netherlands.
Ljubica MaticDivision of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.ORCID 0000-0002-7294-9667
Karolinska Institutet · SEMaastricht University · NLLund University · SEAstraZeneca (Finland) · FIMaastricht University Medical Centre · NLRWTH Aachen University · DEStanford Medicine · USTUM Klinikum · DE

Funding

ALF 20180048Dutch Thrombosis Society 2014.02European Union's Horizon 2020 (INTRICARE 722609)Foundation for Geriatric Diseases at Karolinska Institutet (KI Fonder); German Research FoundationGerman Research Foundation DFG-GO1801/5-1Karolinska Institute research (KI Fonder) and doctoral education (KID) foundation, Foundation for Geriatric Diseases at Karolinska InstitutetNorwegian Research Council and Nattopharma ASA; Netherlands Organization for Scientific Research N.W.O. ZonMW program #40-42600-98-13007 M.K.M.D (Meer Kennis Minder Dieren)Sven and Ebba-Christina Hagberg, Tore Nilsson's, Magnus Bergvall's and Mats Kleberg's FoundationsSwedish Heart-Lung Foundation 201602877Swedish Heart-Lung Foundation 20160384Swedish Heart-Lung Foundation 20180244Swedish Heart-Lung Foundation 20180247Swedish Heart-Lung Foundation 20190196Swedish Heart-Lung Foundation 20190625Swedish Heart-Lung Foundation 20200520Swedish Heart-Lung Foundation 20200621Swedish Research Council 2019-02027
6 · The paper itself

Abstract

rationaleVascular calcification is a prominent feature of late-stage diabetes, renal and cardiovascular disease (CVD), and has been linked to adverse events. Recent studies in patients reported that plasma levels of osteomodulin (OMD), a proteoglycan involved in bone mineralisation, associate with diabetes and CVD. We hypothesised that OMD could be implicated in these diseases via vascular calcification as a common underlying factor and aimed to investigate its role in this context. METHODS AND

resultsIn patients with chronic kidney disease, plasma OMD levels correlated with markers of inflammation and bone turnover, with the protein present in calcified arterial media. Plasma OMD also associated with cardiac calcification and the protein was detected in calcified valve leaflets by immunohistochemistry. In patients with carotid atherosclerosis, circulating OMD was increased in association with plaque calcification as assessed by computed tomography. Transcriptomic and proteomic data showed that OMD was upregulated in atherosclerotic compared to control arteries, particularly in calcified plaques, where OMD expression correlated positively with markers of smooth muscle cells (SMCs), osteoblasts and glycoproteins. Immunostaining confirmed that OMD was abundantly present in calcified plaques, localised to extracellular matrix and regions rich in α-SMA

conclusionWe report a consistent association of both circulating and tissue OMD levels with cardiovascular calcification, highlighting the potential of OMD as a clinical biomarker. OMD was localised in medial and intimal α-SMA

Indexed as

Analysis of VarianceCohort StudiesCross-Sectional StudiesExtracellular Matrix ProteinsHumansLinear ModelsMuscle, SmoothNetherlandsOsteogenesisProspective StudiesProteoglycansStatistics, NonparametricSwedenVascular CalcificationExtracellular Matrix ProteinsosteoadherinProteoglycansaortic valvesatherosclerosiscalcificationchronic kidney diseaseosteogenic transdifferentiationosteomodulinsmooth muscle cells

Identifiers

PMID35184400
PMCPMC8858609
OpenAlexW4213369136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.